Strategy for the treatment of acute myelogenous leukemia based on folate receptor β–targeted liposomal doxorubicin combined with receptor induction using all-trans retinoic acid
- 15 July 2002
- journal article
- Published by American Society of Hematology in Blood
- Vol. 100 (2), 594-602
- https://doi.org/10.1182/blood.v100.2.594
Abstract
Up-regulation of folate receptor (FR) type-β in acute myelogenous leukemia (AML) by all-trans retinoic acid (ATRA) and its restricted normal tissue distribution makes it a potential target for therapeutic intervention. The FR-β in peripheral blood granulocytes was unable to bind folate and appeared to have a variant GPI membrane anchor, evident from its insensitivity to phosphatidylinositol-specific phospholipase C but not nitrous acid. Granulocyte FR-β lacked mutations, and neither deglycosylation nor detergent solubilization restored folate binding. The posttranslational modification causing its nonfunctionality was evidently absent in FR-β from AML cells from patient marrow, which bound folate. From flow cytometric analysis of 78 AML bone marrow specimens of different subtypes, 68% expressed FR-β, most of which were also CD34+. In model cell lines that are FR (−) (KG-1a, L1210, and Chinese hamster ovary [CHO]) or FR (+) (KG-1, L1210 JF, and recombinant CHO-FR–β), selective FR-mediated binding and cytotoxicity was obtained using folate-coated liposomes encapsulating fluorescent calcein (f-L-calcein) and doxorubicin (f-L-DOX), respectively, which could be blocked by 1 mM free folic acid. In the FR-β–expressing KG-1 human AML cells, treatment with ATRA further increased this specificity. In mouse ascites leukemia models generated using L1210JF or KG-1 cells, increased median survival times were obtained with f-L-DOX treatment compared to nontargeted L-DOX. In the KG-1 model, ATRA treatment increased the cure rate with f-L-DOX from 10% to 60%. The above combined data from our 2 laboratories further support the feasibility and potential usefulness of selective ATRA-facilitated liposomal drug delivery in FR-β (+) AMLs.Keywords
This publication has 44 references indexed in Scilit:
- Receptor-Specific Delivery of Liposomes Via Folate-Peg-CholJournal of Liposome Research, 2000
- Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cellNature Medicine, 1997
- Variant GPI Structure in Relation to Membrane-Associated Functions of a Murine Folate ReceptorBiochemistry, 1996
- Preferred Sites of Glycosylphosphatidylinositol Modification in Folate Receptors and Constraints in the Primary Structure of the Hydrophobic Portion of the SignalBiochemistry, 1995
- Folate Receptor Type .gamma. Is Primarily a Secretory Protein Due to Lack of an Efficient Signal for Glycosylphosphatidylinositol Modification: Protein Characterization and Cell Type SpecificityBiochemistry, 1995
- Effect of liposomes on P-glycoprotein function in multidrug resistant cellsBiochemical and Biophysical Research Communications, 1992
- Synthesis and biological evaluation of a fluorescent analog of folic acidBiochemistry, 1991
- Homologous membrane folate binding proteins in human placenta: cloning and sequence of a cDNABiochemistry, 1989
- Purification, properties, and immunological characterization of folate-binding proteins from human leukemia cellsBiochimica et Biophysica Acta (BBA) - General Subjects, 1987
- Characterization of multiple forms of folate-binding protein from human leukemia cellsBiochimica et Biophysica Acta (BBA) - General Subjects, 1986